Related Experiment Video

Updated: Oct 4, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K

[The Relationship between MicroRNA Expression Profiling in Imatinib-Resistant Cell Line K562/G and Potential

Jing Shen1, Huan Wang1, Jing-Shi Wang1

  • 1Department of Hematology, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing 100050, China.

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|February 6, 2022
PubMed
Abstract

Insights

The FOXO3/Bcl-6 signaling pathway is implicated in imatinib resistance in K562/G cells. MicroRNA profiling revealed significant expression differences, suggesting a role for miRNAs in drug resistance mechanisms.

Area of Science:

  • Molecular Biology
  • Oncology
  • Pharmacology

Background:

  • Imatinib resistance is a significant clinical challenge in chronic myeloid leukemia.
  • The FOXO3/Bcl-6 signaling pathway's role in drug resistance is not fully understood.
  • MicroRNAs (miRNAs) are emerging as key regulators in cancer drug resistance.

Purpose of the Study:

  • To investigate the FOXO3/Bcl-6 signaling pathway in the imatinib-resistant K562/G cell line.
  • To explore the involvement of microRNA mechanisms in this drug resistance.
  • To identify specific miRNAs targeting the FOXO3/Bcl-6 pathway.

Main Methods:

  • Drug resistance was assessed using MTT assays.
  • Protein and mRNA expression of FOXO3 and Bcl-6 were analyzed via Western blot and RT-PCR.
  • MicroRNA expression profiling was performed using microarray analysis.

Main Results:

  • FOXO3 and Bcl-6 protein levels were significantly elevated in K562/G cells.
  • FOXO3 mRNA was upregulated, while Bcl-6 mRNA showed no significant change.
  • 109 differentially expressed miRNAs were identified, with 6 specific miRNAs predicted to target the FOXO3/Bcl-6 pathway.

Conclusions:

  • The FOXO3/Bcl-6 signaling pathway plays a role in imatinib resistance in K562/G cells.
  • Significant differences in miRNA expression profiles exist between resistant and sensitive cells.
  • These findings highlight potential miRNA-based therapeutic strategies for overcoming imatinib resistance.
Keywords:
Bcl-6FOXO3chronic myeloid leukemiadrug resistancemiRNA

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

5.8K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K